MetaCap

Cumberland Pharmaceuticals (CPIX) vs Equillium (EQ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cumberland Pharmaceuticals (CPIX) has outperformed Equillium (EQ) over the past year, gaining 193.5% versus a gain of 10.4%. Over five years, CPIX leads with a +161.9% price change compared with -80.4% for EQ. Cumberland Pharmaceuticals is the larger company by market cap ($87.6 million vs $87.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CPIX+193.47%EQ+10.42%
+369%+170%-30%
Nov 21, 20251 yearNov 20, 2026
CPIX+134.54%EQ-79.81%
+258%+73%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CPIX versus EQ key metrics
MetricCPIXEQ
Share price$5.84$1.06
Market cap$87.57M$87.26M
1-day change-7.30%-5.36%
YTD return+46.73%-31.61%
1-year return+193.47%+10.42%
5-year return+161.88%-80.41%
Forward P/E41.71—
EPS (TTM)$-0.57$-0.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.52M—
Revenue growth (YoY)+17.57%—
Net income (latest FY)$-2.84M$-22.40M
Gross margin85.02%—
Operating margin-6.27%—
Net margin-6.37%—
52-week high$9.28$3.54
52-week low$2.00$0.81
Distance from 52-week high-37.07%-70.06%
Analyst consensus—strong_buy
Avg. price target upside—+707.55%
Average volume114.52K544.39K
Shares outstanding15.00M82.32M
Employees8814
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CPIX has outperformed EQ by 183.1 percentage points over the past year.

About Cumberland Pharmaceuticals

CPIX stock →

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.

Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees

About Equillium

EQ stock →

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

CPIX vs EQ FAQ

Which is bigger, Cumberland Pharmaceuticals or Equillium?

Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $87.57M compared with $87.26M for Equillium (EQ).

Which stock has performed better over the past year, CPIX or EQ?

CPIX returned +193.47% over the past 12 months, compared with +10.42% for EQ (price return, excluding dividends). Past performance does not predict future results.

Are Cumberland Pharmaceuticals and Equillium in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons